Low Cerebrospinal Fluid Aβ42 and Aβ40 Are Related to White Matter Lesions in Cognitively Normal Elderly

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2018 Apr 5

PMID 29614655

Citations 10

Authors

Ingmar Skoog

Silke Kern

Henrik Zetterberg

Svante Ostling

Anne Borjesson-Hanson

Xinxin Guo

Kaj Blennow

Affiliations

Soon will be listed here.

Abstract

Background: Low cerebrospinal fluid (CSF) levels of Aβ42 may be the earliest manifestation of Alzheimer's disease (AD). Knowledge on how CSF Aβ interacts with different brain pathologies early in the disease process is limited. We examined how CSF Aβ markers relate to brain atrophy and white matter lesions (WMLs) in octogenarians with and without dementia to explore the earliest pathogenetic pathways of AD in the oldest old.

Objective: To study CSF amyloid biomarkers in relation to brain atrophy and WMLs in 85-year-olds with and without dementia.

Methods: 53 octogenarians took part in neuropsychiatric examinations and underwent both a lumbar puncture and a brain CT scan. CSF levels of Aβ42 and Aβ40 were examined in relation to cerebral atrophy and WMLs. Dementia was diagnosed.

Results: In 85-year-olds without dementia, lower levels of both CSF Aβ42 and CSF Aβ40 were associated with WMLs. CSF Aβ42 also correlated with measures of central atrophy, but not with cortical atrophy. In participants with dementia, lower CSF levels of Aβ42 were related to frontal, temporal, and parietal cortical atrophy but not to WMLs.

Conclusions: Our findings may suggest that there is an interrelationship between Aβ and subcortical WMLs in older persons without dementia. After onset of dementia, low CSF Aβ42, probably representing amyloid deposition in plaques, is associated with cortical atrophy. WMLs may be an earlier manifestation of Aβ deposition than cortical degeneration.

Citing Articles

Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study.

Zhang Y, Ferreira P, Jacobsen E, Bellaver B, Pascoal T, Snitz B Alzheimers Dement. 2024; 20(6):4199-4211.

PMID: 38753951 PMC: 11180930. DOI: 10.1002/alz.13829.

Oligomer-Aβ42 suppress glioma progression via potentiating phagocytosis of microglia.

Lu J, Wang Z, He Z, Hu Y, Duan H, Liu Z CNS Neurosci Ther. 2023; 30(1):e14495.

PMID: 37849438 PMC: 10805446. DOI: 10.1111/cns.14495.

Linking Plasma Amyloid Beta and Neurofilament Light Chain to Intracortical Myelin Content in Cognitively Normal Older Adults.

Fernandez-Alvarez M, Atienza M, Zallo F, Matute C, Capetillo-Zarate E, Cantero J Front Aging Neurosci. 2022; 14:896848.

PMID: 35783126 PMC: 9247578. DOI: 10.3389/fnagi.2022.896848.

Neuroimaging in the Oldest-Old: A Review of the Literature.

Woodworth D, Scambray K, Corrada M, Kawas C, Sajjadi S J Alzheimers Dis. 2021; 82(1):129-147.

PMID: 33998539 PMC: 8717609. DOI: 10.3233/JAD-201578.

Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers.

Cheslow L, Snook A, Waldman S Biomark Med. 2021; 15(8):597-608.

PMID: 33988462 PMC: 8293030. DOI: 10.2217/bmm-2020-0654.

References

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B . Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999; 56(6):673-80. DOI: 10.1001/archneur.56.6.673. View

Querfurth H, LaFerla F . Alzheimer's disease. N Engl J Med. 2010; 362(4):329-44. DOI: 10.1056/NEJMra0909142. View

Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H . Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol. 2008; 63(5):621-31. DOI: 10.1002/ana.21345. View

Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K . Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003; 15(3):169-76. DOI: 10.1159/000068478. View

Fagan A, Roe C, Xiong C, Mintun M, Morris J, Holtzman D . Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007; 64(3):343-9. DOI: 10.1001/archneur.64.3.noc60123. View

Bouwman F, Schoonenboom S, van der Flier W, van Elk E, Kok A, Barkhof F . CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging. 2006; 28(7):1070-4. DOI: 10.1016/j.neurobiolaging.2006.05.006. View

Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson L, Nilsson L . 15-year longitudinal study of blood pressure and dementia. Lancet. 1996; 347(9009):1141-5. DOI: 10.1016/s0140-6736(96)90608-x. View

Zhang X, Zhou K, Wang R, Cui J, Lipton S, Liao F . Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem. 2007; 282(15):10873-80. DOI: 10.1074/jbc.M608856200. View

Stenset V, Hofoss D, Johnsen L, Berstad A, Negaard A, Skinningsrud A . White matter lesion load increases the risk of low CSF Aβ42 in apolipoprotein E-ɛ4 carriers attending a memory clinic. J Neuroimaging. 2009; 21(2):e78-82. DOI: 10.1111/j.1552-6569.2009.00444.x. View

10.

Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

11.

Buchhave P, Minthon L, Zetterberg H, Wallin A, Blennow K, Hansson O . Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012; 69(1):98-106. DOI: 10.1001/archgenpsychiatry.2011.155. View

12.

Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A . Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol. 2009; 17(3):377-82. DOI: 10.1111/j.1468-1331.2009.02808.x. View

13.

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

14.

Selnes P, Blennow K, Zetterberg H, Grambaite R, Rosengren L, Johnsen L . Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res. 2010; 7:10. PMC: 2921347. DOI: 10.1186/1743-8454-7-10. View

15.

Roman G, Tatemichi T, Erkinjuntti T, Cummings J, Masdeu J, Garcia J . Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993; 43(2):250-60. DOI: 10.1212/wnl.43.2.250. View

16.

Schroder J, Pantel J, IDA N, Essig M, Hartmann T, Knopp M . Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol Psychiatry. 1997; 2(6):505-7. DOI: 10.1038/sj.mp.4000313. View

17.

Tabaton M, Caponnetto C, Mancardi G, Loeb C . Amyloid beta protein deposition in brains from elderly subjects with leukoaraiosis. J Neurol Sci. 1991; 106(2):123-7. DOI: 10.1016/0022-510x(91)90248-6. View

18.

de Leon M, Ferris S, George A, Reisberg B, KRICHEFF I, Gershon S . Computed tomography evaluations of brain-behavior relationships in senile dementia of the Alzheimer's type. Neurobiol Aging. 1980; 1(1):69-79. DOI: 10.1016/0197-4580(80)90027-5. View

19.

van Westen D, Lindqvist D, Blennow K, Minthon L, Nagga K, Stomrud E . Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET. Sci Rep. 2016; 6:20709. PMC: 4746584. DOI: 10.1038/srep20709. View

20.

Chalmers K, Wilcock G, Love S . Contributors to white matter damage in the frontal lobe in Alzheimer's disease. Neuropathol Appl Neurobiol. 2005; 31(6):623-31. DOI: 10.1111/j.1365-2990.2005.00678.x. View